Cappella Medical Devices Ltd Expands its Distribution Network to the Middle East and Asia
Published: Oct 13, 2011
GALWAY, Ireland--(BUSINESS WIRE)--Cappella Medical Devices Ltd (Cappella), a medical device company developing dynamic solutions for the treatment of coronary bifurcation disease, is delighted to announce that Doox Medica has been appointed as the exclusive distributor in Middle Eastern territories and the Sideguard® Coronary Stent system has been approved by the Saudi FDA. The Sideguard incorporates Cappella’s proprietary stent design and balloon delivery system and offers the interventional cardiologist a unique product solution for providing ostial protection and side branch preservation for a wide range of bifurcation lesions. Consistent with the strategy to accelerate commercialization in the emerging growth markets Cappella is also seeking market entry of its Sideguard product in India in the near term. These two important developments underline the commitment to expanding the global access to Cappella’s breakthrough bifurcation technology. The entry into Asia represents the next exciting phase of development. Cappella’s commitment to India will in the longer term extend to clinical trials of its next generation of products currently under development that will result in additional commercialization opportunities.